PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review.

Zhou, Maggie; Joshi, Nitin; Raj, Kavitha P; Wakelee, Heather; Neal, Joel W

Zhou, Maggie; Joshi, Nitin; Raj, Kavitha P; Wakelee, Heather; Neal, Joel W.

Affiliation

Zhou M; Department of Medicine, Stanford University, Stanford, CA.
Joshi N; University Healthcare Alliance, Stanford Healthcare, Newark, CA.
Raj KP; University Healthcare Alliance, Stanford Healthcare, Newark, CA.
Wakelee H; Department of Medicine, Division of Oncology, Stanford University, Stanford, CA.
Neal JW; Department of Medicine, Division of Oncology, Stanford University, Stanford, CA. Electronic address: jwneal@stanford.edu.

Clin Lung Cancer ; 22(3): e329-e335, 2021 05.

Article in En | MEDLINE | ID: mdl-32624413

Subject(s)

Immunotherapy/methods; Mesothelioma, Malignant/drug therapy; Pleural Neoplasms/drug therapy; Aged; Aged, 80 and over; B7-H1 Antigen/immunology; Female; Humans; Immune Checkpoint Inhibitors/administration & dosage; Immune Checkpoint Inhibitors/pharmacology; Male; Mesothelioma, Malignant/pathology; Middle Aged; Pleural Neoplasms/pathology; Programmed Cell Death 1 Receptor/immunology; Retrospective Studies

Key words

Case series; Immunotherapy; Mesothelioma; PD-L1

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pleural Neoplasms / Mesothelioma, Malignant / Immunotherapy Type of study: Observational_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Clin Lung Cancer Journal subject: NEOPLASIAS Year: 2021 Document type: Article Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google